RECRUITING

Disrupting Fear-based Memory Consolidation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This project represents a unique collaborative opportunity to pursue the essential proof-of-principle demonstration that non-invasive interference of sensory cortical memory consolidation shortly after an emotional experience can attenuate the cued fear response and potentially reduce the risk of developing post-traumatic stress disorder (PTSD). If successful, the study results would anchor a potential advance in the treatment of patients after a traumatic event and seed future animal and clinical studies of emotional sensory cortical memory consolidation to reduce the prevalence and negative sequelae of PTSD.

Official Title

Forgetting Fear: Establishing a Novel Non-invasive Approach to Disrupt Fear-based Sensory Memory Consolidation in Humans

Quick Facts

Study Start:2022-11-28
Study Completion:2028-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05560113

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ability to provide informed consent
  2. * Willingness to participate in study
  3. * No history of musculoskeletal impairment or neurological disease
  4. * Clinical diagnosis of PTSD for individuals in the PTSD group.
  1. * Any participant outside the age range
  2. * Participants that show signs of dementia (score \< 20 on the Montreal Cognitive Assessment)
  3. * Participants that have a history of major head trauma, a neurodegenerative disorder, or recent (\<6 months) substance abuse;
  4. * Participants that had a recent history of Central Nervous System (CNS) active drugs that may influence cortical excitability or learning; or
  5. * Participants that report contraindications to TMS or MRI - if participating in the TMS/MRI experiments
  6. * Current psychoactive medication usage
  7. * Current symptoms of psychosis or bipolar disorder (as indicated by study staff through a clinical interview as part of that study).
  8. * The study will exclude adults unable to consent, individuals who are not yet adults, pregnant women and prisoners on scientific grounds and to minimize risk.

Contacts and Locations

Study Contact

Michael Borich, PhD
CONTACT
404-712-5512
michael.borich@emory.edu
Jennifer Stevens, PhD
CONTACT
404-778-1698
jswils4@emory.edu

Principal Investigator

Michael Borich, PhD
PRINCIPAL_INVESTIGATOR
Emory University

Study Locations (Sites)

Emory Rehabilitation Hospital
Atlanta, Georgia, 30322
United States
Emory University Hospital
Atlanta, Georgia, 30322
United States

Collaborators and Investigators

Sponsor: Emory University

  • Michael Borich, PhD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-28
Study Completion Date2028-12

Study Record Updates

Study Start Date2022-11-28
Study Completion Date2028-12

Terms related to this study

Keywords Provided by Researchers

  • Fear
  • Transcranial Magnetic Stimulation
  • Memory

Additional Relevant MeSH Terms

  • Post-Traumatic Stress Disorder